secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2023-04-18T23:59:59+00:00
Accession:  0001104659-23-046455
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports positive early Phase 1 data for IMM-1-104; accelerates RP2D timeline to early 2024
--------------------------------------------------------------------------------

- IMM-1-104 shows >90% pERK inhibition at 160mg QD; PK Cmax >2,000 ng/mL; half-life ~2 hours.
- No dose-limiting toxicities or SAEs; only Grade 1 drug-related AEs; well tolerated across four patients.
- RP2D announcement accelerated to early 2024 from prior guidance of mid-2024.
- Preliminary cash $91.5M at March 31, 2023; expected funding into Q4 2024.
- Data from patients with pancreatic and colorectal cancer with KRAS G12D, G12V, NRAS Q61L, Q61K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000110465923046455/0001104659-23-046455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000110465923046455/tm2312981d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-046455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer